Mechanisms of Primary and Secondary Resistance to Immune Checkpoint Inhibitors in Cancer
Immune checkpoint inhibitors (ICPis) have revolutionized cancer therapy with broad activities against a wide range of malignancies. However, in many malignancies their efficacy remains limited due to the primary resistance. Furthermore, a high percentage of patients develop progression due to the se...
Main Authors: | , , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2019-01-01
|
Series: | Medical Sciences |
Subjects: | |
Online Access: | https://www.mdpi.com/2076-3271/7/2/14 |